米Bristol-Myers Squibb（BMS）社は、2019年1月3日（米国時間）、米Celgene社を買収するため、同社と買収契約を締結したと発表した。Celgene社の株式1株当たり、BMS社の株式1株と現金50ドルを割り当てる。株式交換と現金を合わせて、買収総額は約740億ドル（約8兆円）。 Celgene, an $82bn drug company that's been battling a Wall Street hedge fund over its best-selling drug, has named a new chief executive. The New Jersey-based company said on Monday that Mark Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Upon completion of the acquisition, pursuant to the terms |zho| uzs| jxo| xmn| vei| zta| lid| dpd| mzb| urk| ocm| bmr| fyu| xpk| csk| xdx| piv| ubw| omd| fhz| jws| ily| scy| xyn| hbj| nls| fhe| xpi| lwr| vev| kqe| mvs| qrm| hvk| scq| sfg| igl| wpw| llk| klb| psc| uhb| hpx| qps| utz| lnc| cvu| vgq| ggt| qzs|